Medtronic Misses Mid-Year Mark With 'Disappointing' 3% Growth
Executive Summary
The medtech giant says slow sales in its cardiovascular and diabetes businesses while it awaits important product approvals were a drag on its overall revenues during the second fiscal quarter of 2017.
You may also be interested in...
OUS Approvals Analysis: Medtronic Records Another Stack Of Overseas Approvals
With 28 approvals, including 22 CE Marks, February 2017 was the biggest month for non-US medical device approvals on Medtech Insight’s Approvals Tracker since June last year, which had 31 approvals including 27 CE Marks.
New Products Drive Medtronic’s Revenue, Profit Growth In Q3
The medtech giant announced 6% revenue growth, led by the cardiac and vascular and diabetes groups, both of which are enjoying strong market demand for new products. Medtronic expects to continue growing revenues by about five percent annually to maintain double-digit earnings growth.
OUS Approvals Analysis: Slow Finish To 2016, But Still Ahead Of 2015
2016 finished with just two more non-US medical device approvals than 2015; December was by far the slowest month of the year for approvals from outside the US with just 11.